364
Participants
Start Date
August 11, 2023
Primary Completion Date
November 30, 2026
Study Completion Date
December 29, 2026
SHR-A1811 combined with Pyrotinib.
SHR-A1811 combined with Pyrotinib
SHR-A1811 combined with other antitumor therapies
SHR-A1811 combined with other antitumor therapies
RECRUITING
Peking University Cancer Hospital & Institute-Department of Gastrointestinal Oncology, Beijing
RECRUITING
Anhui Provincial Hospital, Hefei
RECRUITING
Tianjin Medical University Cancer Institute and Hospital-Department of digestive oncology, Tianjin
RECRUITING
The First Affiliated Hospital of Nanchang University, Nanchang
RECRUITING
The Second Affiliated Hospital of Nanchang University, Nanchang
RECRUITING
The First Affiliated Hospital of Chongqing Medical University, Chongqing
RECRUITING
Hunan Cancer Hospital, Changsha
RECRUITING
Hubei Cancer Hospital-Department of Abdominal Oncology, Wuhan
RECRUITING
Henan Cancer Hospital, Zhengzhou
RECRUITING
The First Affiliated Hospital of Zhengzhou University-Department of Medical Oncology, Zhengzhou
RECRUITING
Guangxi Medical University Affiliated Tumor Hospital, Nanning
RECRUITING
The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an
RECRUITING
The Fourth Hospital of Hebei Medical University, Shijiazhuang
RECRUITING
Harbin Medical University Cancer Hospital-The Eighth Department of Internal Medicine, Harbin
RECRUITING
Shanxi Provincial Cancer Hospital-Gastroenterology Department, Taiyuan
Jiangsu HengRui Medicine Co., Ltd.
INDUSTRY